These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 25877635)

  • 41. Prevalence of neutralising antibodies to interferon-beta and clinical response in Chinese patients with relapsing multiple sclerosis.
    Lau AY; Ip WK; Au C; Lau KK; Wong W; Yip KK; Yeung J; Li SH; Li P; Lee R; Siu D; Abrigo J; Wong A; Mok V; Chan E
    Mult Scler J Exp Transl Clin; 2017; 3(4):2055217317733485. PubMed ID: 29051830
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neutralizing Antibodies Against Interferon-Beta in Korean Patients with Multiple Sclerosis.
    Hyun JW; Kim G; Kim Y; Kong B; Joung A; Park NY; Jang H; Shin HJ; Kim SH; Ahn SW; Shin HY; Huh SY; Kim W; Park MS; Kim BJ; Kim BJ; Oh J; Kim HJ
    J Clin Neurol; 2018 Apr; 14(2):186-190. PubMed ID: 29504299
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Measurement of neutralising antibodies to type I interferons by gene expression assays specific for type 1 interferon-inducible 6-16 mRNA.
    Moore M; Meager A; Wadhwa M; Burns C
    J Pharm Biomed Anal; 2009 Feb; 49(2):534-9. PubMed ID: 19097723
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
    Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
    [TBL] [Abstract][Full Text] [Related]  

  • 45. IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression.
    Reder AT; Velichko S; Yamaguchi KD; Hamamcioglu K; Ku K; Beekman J; Wagner TC; Perez HD; Salamon H; Croze E
    J Interferon Cytokine Res; 2008 May; 28(5):317-31. PubMed ID: 18547162
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis.
    Sorensen PS; Ross C; Clemmesen KM; Bendtzen K; Frederiksen JL; Jensen K; Kristensen O; Petersen T; Rasmussen S; Ravnborg M; Stenager E; Koch-Henriksen N;
    Lancet; 2003 Oct; 362(9391):1184-91. PubMed ID: 14568740
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High-dose intravenous interferon-beta in multiple sclerosis patients with high-titer neutralizing antibodies (HINABS II) - A pilot study.
    Hegen H; Guger M; Harrer A; Hoelzl M; Kraus J; Skrobal A; Schautzer F; Schmidegg S; Schocke M; Deisenhammer F
    Mult Scler Relat Disord; 2014 Mar; 3(2):220-6. PubMed ID: 25878009
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Routine interferon-neutralising antibody testing in patients with relapsing-remitting multiple sclerosis.
    Foley P; Reilly P; Coulson A; O'Riordan JI
    J R Coll Physicians Edinb; 2010 Jun; 40(2):105-10. PubMed ID: 21125049
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
    Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis.
    Gavasso S; Gjertsen B; Anderssen E; Myhr K; Vedeler C
    Mult Scler; 2012 Aug; 18(8):1116-24. PubMed ID: 22287540
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BAb and MxA as functional biomarkers in routine clinical laboratories for the determination of anti-IFN-beta antibodies and their bioactivity levels in multiple sclerosis patients.
    Cakal B; Uygunoglu U; Saip S; Altintas A; Siva A; Badur S
    J Immunoassay Immunochem; 2014; 35(4):398-411. PubMed ID: 24547871
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biological monitoring of IFN-β therapy in Multiple Sclerosis.
    Bertolotto A; Granieri L; Marnetto F; Valentino P; Sala A; Capobianco M; Malucchi S; Di Sapio A; Malentacchi M; Matta M; Caldano M
    Cytokine Growth Factor Rev; 2015 Apr; 26(2):241-8. PubMed ID: 25596967
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic Plasma Exchange in Multiple Sclerosis Patients with Abolished Interferon-beta Bioavailability.
    Giedraitiene N; Kaubrys G; Kizlaitiene R; Bagdonaite L; Griskevicius L; Valceckiene V; Stoskus M
    Med Sci Monit; 2015 May; 21():1512-9. PubMed ID: 26009248
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.
    Gilli F; Valentino P; Caldano M; Granieri L; Capobianco M; Malucchi S; Sala A; Marnetto F; Bertolotto A
    Neurology; 2008 Dec; 71(24):1940-7. PubMed ID: 18971450
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neutralizing antibodies to interferon.
    Noronha A
    Neurology; 2007 Jun; 68(24 Suppl 4):S16-22. PubMed ID: 17562846
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-interferon-α neutralizing antibody is associated with nonresponse to pegylated interferon-α plus ribavirin in chronic hepatitis C.
    Matsuda F; Torii Y; Enomoto H; Kuga C; Aizawa N; Iwata Y; Saito M; Imanishi H; Shimomura S; Nakamura H; Tanaka H; Iijima H; Tsutsui H; Tanaka Y; Nishiguchi S
    J Viral Hepat; 2012 Oct; 19(10):694-703. PubMed ID: 22967100
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Are corticosteroids efficacious for preventing or treating neutralizing antibodies in multiple sclerosis patients treated with beta-interferons? A critically appraised topic.
    Zarkou S; Carter JL; Wellik KE; Demaerschalk BM; Wingerchuk DM
    Neurologist; 2010 May; 16(3):212-4. PubMed ID: 20445436
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
    Perini P; Calabrese M; Biasi G; Gallo P
    J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging.
    Chiu AW; Ehrmantraut M; Richert ND; Ikonomidou VN; Pellegrini S; McFarland HF; Frank JA; Bagnato F
    Clin Exp Immunol; 2007 Oct; 150(1):61-7. PubMed ID: 17666095
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mx1 and IP-10: biomarkers to measure IFN-beta activity in mice following gene-based delivery.
    Petry H; Cashion L; Szymanski P; Ast O; Orme A; Gross C; Bauzon M; Brooks A; Schaefer C; Gibson H; Qian H; Rubanyi GM; Harkins RN
    J Interferon Cytokine Res; 2006 Oct; 26(10):699-705. PubMed ID: 17032164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.